Send to

Choose Destination
Semin Cancer Biol. 1998;8(5):369-78.

Reactivation of mutant p53: a new strategy for cancer therapy.

Author information

Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.


The specific DNA binding activity of p53 is crucial for its tumor suppression function. Naturally occurring mutant forms of p53 are deficient for specific DNA binding. However, several studies have indicated that their specific DNA binding can be reactivated. Short peptides derived from the p53 C-terminus can reactivate at least some mutant p53 proteins and trigger a p53-dependent biological response. These results may provide the basis for the design of p53-reactivating anti-cancer drugs.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center